94 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. It is expected to enroll about 50 subjects, with 16-week data … to long-lasting, disease-modifying intervention for DME
UBX1325 16-week safety and efficacy data from the Phase 2b ASPIRE DME study expected
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
(foselutoclax) or any future product candidates;
our expectations regarding the potential benefits, activity, effectiveness, and safety of our drug candidates
8-K
EX-99.1
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
diseases of aging, today reported financial results for the third quarter ended September 30, 2023.
“Following positive efficacy and safety data at 48 … , randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. It is expected
8-K
EX-99.1
jzreuv1ythajr9k
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
EX-99.1
a95dfi0 r6z9qzg6jq
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.2
bgu9bqfa
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
r7bh 76zs
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
sypkhv6avnc
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
EX-99.1
8xdfme8g
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.2
bpd6ep44w7w1u9571m7
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
fdfajvkp7
25 Oct 22
Prospectus supplement for primary offering
9:39pm